Top Markets
Coin of the day
Alimera Sciences, Inc. Alimera Sciences, Inc.

Alimera Sciences, Inc.

ALIM
Rangering i aksjer #26672
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and... Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Aksjekurs
$5.54
Sist synkronisert: 2024-09-18
Markedsverdi
$38.76M
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Alimera Sciences, Inc. (ALIM)

Kategori

P/S-forhold for Alimera Sciences, Inc. (ALIM)
P/S-forhold per August 2026 TTM: 3.73
Ifølge Alimera Sciences, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 3.73. Ved slutten av 2022 hadde selskapet et P/S-forhold på 0.35.
P/S-historikk for Alimera Sciences, Inc. fra 2006 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
2026 (TTM) 3.73 172.33%
2023 1.37 290.38%
2022 0.35 -38.88%
2021 0.57 34.85%
2020 0.43 -36.60%
2019 0.67 -50.18%
2018 1.35 -45.77%
2017 2.48 49.38%
2016 1.66 -65.35%
2015 4.79 -81.96%
2014 26.57 -66.49%
2013 79.27 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
P/S-forhold for lignende selskaper eller konkurrenter